ArticleDiscover oncology2026
ADAMDEC1 predicts prognosis and immunotherapy response in a pan-cancer study with experimental validation.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundADAMDEC1 (a disintegrin and metalloproteinase domain-like protein decysin-1) is linked to immune disorders and cancers, but its pan-cancer role remains unclear.
methodsWe analyzed ADAMDEC1 using The Cancer Genome Atlas (TCGA), Genotype-Tissue Expression (GTEx), Gene Expression Omnibus (GEO), and Molecular Taxonomy of Breast Cancer International Consortium (METABRIC) for expression, prognosis, immune infiltration, and therapy response. Single-cell RNA sequencing (scRNA-seq) and genomic alterations were examined. Gene set enrichment analysis (GSEA) assessed pathways. Immunohistochemistry (IHC) validated ADAMDEC1 in esophageal cancer (ESCA) tissue microarray (n = 48). Immunotherapy response was predicted using Tumor Immune Dysfunction and Exclusion (TIDE) and independent cohorts.
resultsADAMDEC1 was dysregulated across cancers with context-dependent prognosis: high expression correlated with poor survival in lower-grade glioma (LGG) and uveal melanoma (UVM), but better outcomes in ovarian cancer (OV) and skin cutaneous melanoma (SKCM). Single-cell analysis revealed a dichotomy: in UVM, ADAMDEC1 was mainly in tumor-associated macrophages; in SKCM, it was broadly expressed across malignant, immune, and stromal cells. DNA methylation inversely correlated with expression in 20 cancers. ADAMDEC1 linked to immune infiltration and immunomodulatory genes including programmed cell death protein 1 (PD-1). In ESCA, ADAMDEC1 was elevated in metastasis and positively correlated with PD-1. ADAMDEC1 predicted immunotherapy response comparably to conventional biomarkers.
conclusionsADAMDEC1 is a context-dependent immune regulator with prognostic direction determined by cellular origin, supporting its investigation as a therapeutic target and biomarker in precision oncology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.